Colour-duplex  ||| S:0 E:14 ||| JJ
ultrasonography  ||| S:14 E:30 ||| NN
of  ||| S:30 E:33 ||| IN
the  ||| S:33 E:37 ||| DT
temporal  ||| S:37 E:46 ||| NN
and  ||| S:46 E:50 ||| CC
ophthalmic  ||| S:50 E:61 ||| JJ
arteries  ||| S:61 E:70 ||| NNS
in  ||| S:70 E:73 ||| IN
the  ||| S:73 E:77 ||| DT
diagnosis  ||| S:77 E:87 ||| NN
and  ||| S:87 E:91 ||| CC
follow-up  ||| S:91 E:101 ||| JJ
of  ||| S:101 E:104 ||| IN
giant  ||| S:104 E:110 ||| JJ
cell  ||| S:110 E:115 ||| NN
arteritis  ||| S:115 E:125 ||| NN
To  ||| S:125 E:128 ||| TO
evaluate  ||| S:128 E:137 ||| VB
the  ||| S:137 E:141 ||| DT
diagnostic  ||| S:141 E:152 ||| JJ
value  ||| S:152 E:158 ||| NN
of  ||| S:158 E:161 ||| IN
colour-duplex  ||| S:161 E:175 ||| JJ
ultrasonography  ||| S:175 E:191 ||| NNS
( ||| S:191 E:192 ||| -LRB-
CDU ||| S:192 E:195 ||| NNP
)  ||| S:195 E:197 ||| -RRB-
of  ||| S:197 E:200 ||| IN
the  ||| S:200 E:204 ||| DT
temporal  ||| S:204 E:213 ||| NN
and  ||| S:213 E:217 ||| CC
ophthalmic  ||| S:217 E:228 ||| JJ
arteries  ||| S:228 E:237 ||| NNS
in  ||| S:237 E:240 ||| IN
the  ||| S:240 E:244 ||| DT
diagnosis  ||| S:244 E:254 ||| NN
of  ||| S:254 E:257 ||| IN
giant  ||| S:257 E:263 ||| JJ
cell  ||| S:263 E:268 ||| NN
arteritis  ||| S:268 E:278 ||| NNS
( ||| S:278 E:279 ||| -LRB-
GCA ||| S:279 E:282 ||| NNP
)  ||| S:282 E:284 ||| -RRB-
and  ||| S:284 E:288 ||| CC
its  ||| S:288 E:292 ||| PRP$
usefulness  ||| S:292 E:303 ||| NN
in  ||| S:303 E:306 ||| IN
the  ||| S:306 E:310 ||| DT
follow-up  ||| S:310 E:320 ||| JJ
of  ||| S:320 E:323 ||| IN
the  ||| S:323 E:327 ||| DT
disease ||| S:327 E:334 ||| NN
.  ||| S:334 E:336 ||| .
Furthermore ||| S:336 E:347 ||| RB
,  ||| S:347 E:349 ||| ,
to  ||| S:349 E:352 ||| TO
examine  ||| S:352 E:360 ||| VB
the  ||| S:360 E:364 ||| DT
relationship  ||| S:364 E:377 ||| NN
between  ||| S:377 E:385 ||| IN
CDU  ||| S:385 E:389 ||| NNP
abnormalities  ||| S:389 E:403 ||| NN
in  ||| S:403 E:406 ||| IN
ophthalmic  ||| S:406 E:417 ||| JJ
arteries  ||| S:417 E:426 ||| NNS
and  ||| S:426 E:430 ||| CC
blindness ||| S:430 E:439 ||| NN
.  ||| S:439 E:441 ||| .
This  ||| S:441 E:446 ||| DT
is  ||| S:446 E:449 ||| VBZ
a  ||| S:449 E:451 ||| DT
prospective  ||| S:451 E:463 ||| JJ
study  ||| S:463 E:469 ||| NN
of  ||| S:469 E:472 ||| IN
all  ||| S:472 E:476 ||| DT
patients  ||| S:476 E:485 ||| NNS
with  ||| S:485 E:490 ||| IN
clinical  ||| S:490 E:499 ||| JJ
suspicion  ||| S:499 E:509 ||| NN
of  ||| S:509 E:512 ||| IN
GCA  ||| S:512 E:516 ||| NNP
or  ||| S:516 E:519 ||| CC
polymyalgia  ||| S:519 E:531 ||| JJ
rheumatica  ||| S:531 E:542 ||| NNS
( ||| S:542 E:543 ||| -LRB-
PMR ||| S:543 E:546 ||| NNP
)  ||| S:546 E:548 ||| -RRB-
seen  ||| S:548 E:553 ||| VBN
consecutively  ||| S:553 E:567 ||| VBN
at  ||| S:567 E:570 ||| IN
the  ||| S:570 E:574 ||| DT
Internal  ||| S:574 E:583 ||| NNP
Medicine  ||| S:583 E:592 ||| NNP
Department  ||| S:592 E:603 ||| NNP
at  ||| S:603 E:606 ||| IN
Vall  ||| S:606 E:611 ||| NNP
d ||| S:611 E:612 ||| NN
' ||| S:612 E:613 ||| POS
Hebron  ||| S:613 E:620 ||| NNP
University  ||| S:620 E:631 ||| NNP
Hospital ||| S:631 E:639 ||| NNP
,  ||| S:639 E:641 ||| ,
Spain ||| S:641 E:646 ||| NNP
,  ||| S:646 E:648 ||| ,
between  ||| S:648 E:656 ||| IN
March  ||| S:656 E:662 ||| NNP
2003  ||| S:662 E:667 ||| CD
and  ||| S:667 E:671 ||| CC
July  ||| S:671 E:676 ||| NNP
2006 ||| S:676 E:680 ||| CD
.  ||| S:680 E:682 ||| .
Patients  ||| S:682 E:691 ||| NNS
were  ||| S:691 E:696 ||| VBD
evaluated  ||| S:696 E:706 ||| VBN
with  ||| S:706 E:711 ||| IN
regard  ||| S:711 E:718 ||| NN
to  ||| S:718 E:721 ||| TO
the  ||| S:721 E:725 ||| DT
sensitivity  ||| S:725 E:737 ||| NN
and  ||| S:737 E:741 ||| CC
specificity  ||| S:741 E:753 ||| NN
of  ||| S:753 E:756 ||| IN
the  ||| S:756 E:760 ||| DT
dark  ||| S:760 E:765 ||| JJ
halo  ||| S:765 E:770 ||| JJ
sign  ||| S:770 E:775 ||| NN
in  ||| S:775 E:778 ||| IN
the  ||| S:778 E:782 ||| DT
temporal  ||| S:782 E:791 ||| JJ
artery  ||| S:791 E:798 ||| NN
for  ||| S:798 E:802 ||| IN
the  ||| S:802 E:806 ||| DT
diagnosis  ||| S:806 E:816 ||| NN
of  ||| S:816 E:819 ||| IN
GCA ||| S:819 E:822 ||| NNP
,  ||| S:822 E:824 ||| ,
as  ||| S:824 E:827 ||| RB
well  ||| S:827 E:832 ||| RB
as  ||| S:832 E:835 ||| IN
the  ||| S:835 E:839 ||| DT
sensitivity  ||| S:839 E:851 ||| NN
and  ||| S:851 E:855 ||| CC
specificity  ||| S:855 E:867 ||| NN
of  ||| S:867 E:870 ||| IN
the  ||| S:870 E:874 ||| DT
presence  ||| S:874 E:883 ||| NN
of  ||| S:883 E:886 ||| IN
stenosis  ||| S:886 E:895 ||| NN
in  ||| S:895 E:898 ||| IN
temporal  ||| S:898 E:907 ||| NN
and ||| S:907 E:910 ||| CC
/ ||| S:910 E:911 ||| NNP
or  ||| S:911 E:914 ||| CC
ophthalmic  ||| S:914 E:925 ||| JJ
arteries ||| S:925 E:933 ||| NNS
.  ||| S:933 E:935 ||| .
Additionally ||| S:935 E:947 ||| RB
,  ||| S:947 E:949 ||| ,
the  ||| S:949 E:953 ||| DT
usefulness  ||| S:953 E:964 ||| NN
of  ||| S:964 E:967 ||| IN
the  ||| S:967 E:971 ||| DT
dark  ||| S:971 E:976 ||| JJ
halo  ||| S:976 E:981 ||| JJ
sign  ||| S:981 E:986 ||| NN
in  ||| S:986 E:989 ||| IN
the  ||| S:989 E:993 ||| DT
follow-up  ||| S:993 E:1003 ||| JJ
of  ||| S:1003 E:1006 ||| IN
GCA  ||| S:1006 E:1010 ||| NNP
was  ||| S:1010 E:1014 ||| VBD
addressed ||| S:1014 E:1023 ||| VBN
.  ||| S:1023 E:1025 ||| .
Forty-seven  ||| S:1025 E:1037 ||| JJ
patients  ||| S:1037 E:1046 ||| NNS
( ||| S:1046 E:1047 ||| -LRB-
30  ||| S:1047 E:1050 ||| CD
with  ||| S:1050 E:1055 ||| IN
GCA ||| S:1055 E:1058 ||| NNP
,  ||| S:1058 E:1060 ||| ,
17  ||| S:1060 E:1063 ||| CD
with  ||| S:1063 E:1068 ||| IN
PMR ||| S:1068 E:1071 ||| NNP
)  ||| S:1071 E:1073 ||| -RRB-
and  ||| S:1073 E:1077 ||| CC
13  ||| S:1077 E:1080 ||| CD
controls  ||| S:1080 E:1089 ||| NNS
were  ||| S:1089 E:1094 ||| VBD
included  ||| S:1094 E:1103 ||| VBN
in  ||| S:1103 E:1106 ||| IN
the  ||| S:1106 E:1110 ||| DT
study ||| S:1110 E:1115 ||| NN
.  ||| S:1115 E:1117 ||| .
The  ||| S:1117 E:1121 ||| DT
sensitivity  ||| S:1121 E:1133 ||| NN
and  ||| S:1133 E:1137 ||| CC
specificity  ||| S:1137 E:1149 ||| NN
for  ||| S:1149 E:1153 ||| IN
the  ||| S:1153 E:1157 ||| DT
diagnosis  ||| S:1157 E:1167 ||| NN
of  ||| S:1167 E:1170 ||| IN
biopsy-proven  ||| S:1170 E:1184 ||| NNP
GCA  ||| S:1184 E:1188 ||| NNP
were  ||| S:1188 E:1193 ||| VBD
higher  ||| S:1193 E:1200 ||| JJR
for  ||| S:1200 E:1204 ||| IN
the  ||| S:1204 E:1208 ||| DT
temporal  ||| S:1208 E:1217 ||| JJ
halo  ||| S:1217 E:1222 ||| NNS
( ||| S:1222 E:1223 ||| -LRB-
72 ||| S:1223 E:1225 ||| CD
%  ||| S:1225 E:1227 ||| NN
in  ||| S:1227 E:1230 ||| IN
both  ||| S:1230 E:1235 ||| DT
cases ||| S:1235 E:1240 ||| NNS
)  ||| S:1240 E:1242 ||| -RRB-
than  ||| S:1242 E:1247 ||| IN
for  ||| S:1247 E:1251 ||| IN
temporal  ||| S:1251 E:1260 ||| JJ
artery  ||| S:1260 E:1267 ||| NN
stenosis  ||| S:1267 E:1276 ||| NNS
( ||| S:1276 E:1277 ||| -LRB-
41 ||| S:1277 E:1279 ||| CD
%  ||| S:1279 E:1281 ||| NN
and  ||| S:1281 E:1285 ||| CC
89 ||| S:1285 E:1287 ||| CD
% ||| S:1287 E:1288 ||| NN
,  ||| S:1288 E:1290 ||| ,
respectively ||| S:1290 E:1302 ||| RB
) ||| S:1302 E:1303 ||| -RRB-
,  ||| S:1303 E:1305 ||| ,
or  ||| S:1305 E:1308 ||| CC
for  ||| S:1308 E:1312 ||| IN
ophthalmic  ||| S:1312 E:1323 ||| JJ
artery  ||| S:1323 E:1330 ||| NN
stenosis  ||| S:1330 E:1339 ||| NNS
( ||| S:1339 E:1340 ||| -LRB-
58 ||| S:1340 E:1342 ||| CD
%  ||| S:1342 E:1344 ||| NN
and  ||| S:1344 E:1348 ||| CC
89 ||| S:1348 E:1350 ||| CD
% ||| S:1350 E:1351 ||| NN
,  ||| S:1351 E:1353 ||| ,
respectively ||| S:1353 E:1365 ||| RB
) ||| S:1365 E:1366 ||| -RRB-
.  ||| S:1366 E:1368 ||| .
Disappearance  ||| S:1368 E:1382 ||| NN
of  ||| S:1382 E:1385 ||| IN
the  ||| S:1385 E:1389 ||| DT
halo  ||| S:1389 E:1394 ||| NN
was  ||| S:1394 E:1398 ||| VBD
observed  ||| S:1398 E:1407 ||| VBN
in  ||| S:1407 E:1410 ||| IN
50 ||| S:1410 E:1412 ||| CD
%  ||| S:1412 E:1414 ||| NN
of  ||| S:1414 E:1417 ||| IN
patients  ||| S:1417 E:1426 ||| NNS
six  ||| S:1426 E:1430 ||| CD
months  ||| S:1430 E:1437 ||| NNS
after  ||| S:1437 E:1443 ||| IN
diagnosis ||| S:1443 E:1452 ||| NN
,  ||| S:1452 E:1454 ||| ,
although  ||| S:1454 E:1463 ||| IN
all  ||| S:1463 E:1467 ||| DT
patients  ||| S:1467 E:1476 ||| NNS
were  ||| S:1476 E:1481 ||| VBD
in  ||| S:1481 E:1484 ||| IN
clinical  ||| S:1484 E:1493 ||| JJ
remission ||| S:1493 E:1502 ||| NN
,  ||| S:1502 E:1504 ||| ,
and  ||| S:1504 E:1508 ||| CC
laboratory  ||| S:1508 E:1519 ||| NN
parameters  ||| S:1519 E:1530 ||| NNS
were  ||| S:1530 E:1535 ||| VBD
within  ||| S:1535 E:1542 ||| IN
normal  ||| S:1542 E:1549 ||| JJ
values ||| S:1549 E:1555 ||| NNS
.  ||| S:1555 E:1557 ||| .
CDU  ||| S:1557 E:1561 ||| NNP
of  ||| S:1561 E:1564 ||| IN
the  ||| S:1564 E:1568 ||| DT
temporal  ||| S:1568 E:1577 ||| JJ
arteries  ||| S:1577 E:1586 ||| NNS
may  ||| S:1586 E:1590 ||| MD
be  ||| S:1590 E:1593 ||| VB
a  ||| S:1593 E:1595 ||| DT
valid  ||| S:1595 E:1601 ||| JJ
tool  ||| S:1601 E:1606 ||| NN
in  ||| S:1606 E:1609 ||| IN
the  ||| S:1609 E:1613 ||| DT
diagnosis  ||| S:1613 E:1623 ||| NN
of  ||| S:1623 E:1626 ||| IN
GCA ||| S:1626 E:1629 ||| NNP
.  ||| S:1629 E:1631 ||| .
However ||| S:1631 E:1638 ||| RB
,  ||| S:1638 E:1640 ||| ,
its  ||| S:1640 E:1644 ||| PRP$
role  ||| S:1644 E:1649 ||| NN
in  ||| S:1649 E:1652 ||| IN
the  ||| S:1652 E:1656 ||| DT
follow  ||| S:1656 E:1663 ||| VB
up  ||| S:1663 E:1666 ||| RP
of  ||| S:1666 E:1669 ||| IN
the  ||| S:1669 E:1673 ||| DT
disease  ||| S:1673 E:1681 ||| NN
deserves  ||| S:1681 E:1690 ||| VBZ
re-evaluation ||| S:1690 E:1703 ||| JJ
.  ||| S:1703 E:1705 ||| .
CDU  ||| S:1705 E:1709 ||| NNP
of  ||| S:1709 E:1712 ||| IN
the  ||| S:1712 E:1716 ||| DT
ophthalmic  ||| S:1716 E:1727 ||| JJ
arteries  ||| S:1727 E:1736 ||| NNS
is  ||| S:1736 E:1739 ||| VBZ
less  ||| S:1739 E:1744 ||| RBR
useful  ||| S:1744 E:1751 ||| JJ
for  ||| S:1751 E:1755 ||| IN
CGA  ||| S:1755 E:1759 ||| NNP
diagnosis  ||| S:1759 E:1769 ||| NN
and  ||| S:1769 E:1773 ||| CC
no  ||| S:1773 E:1776 ||| DT
relationship  ||| S:1776 E:1789 ||| NN
with  ||| S:1789 E:1794 ||| IN
blindness  ||| S:1794 E:1804 ||| NN
is  ||| S:1804 E:1807 ||| VBZ
suspected ||| S:1807 E:1816 ||| VBN
.  ||| S:1816 E:1818 ||| .
